

# Stephan von Gunten

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3714150/publications.pdf>

Version: 2024-02-01

77  
papers

3,418  
citations

172457  
29  
h-index

149698  
56  
g-index

77  
all docs

77  
docs citations

77  
times ranked

3936  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diversification of IgA Antibody Specificities by Mild Chemical Modification?. <i>Pharmacology</i> , 2022, , 1-2.	2.2	1
2	Therapeutic antibody glycosylation impacts antigen recognition and immunogenicity. <i>Immunology</i> , 2022, 166, 380-407.	4.4	6
3	Digest the Sugar, Kill the Parasite: A New Experimental Concept in Treating Alveolar Echinococcosis. <i>Pharmacology</i> , 2021, 106, 3-8.	2.2	4
4	Glycan-specific IgG anti-IgE autoantibodies are protective against allergic anaphylaxis in a murine model. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1430-1441.	2.9	11
5	Lack of IRF6 Disrupts Human Epithelial Homeostasis by Altering Colony Morphology, Migration Pattern, and Differentiation Potential of Keratinocytes. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 718066.	3.7	4
6	Targeting sialylation to treat central nervous system diseases. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 998-1008.	8.7	15
7	Targeting the Laminated Layer of <i>Echinococcus multilocularis</i> as a Potential Therapeutic Strategy. <i>Pharmacology</i> , 2021, 106, 1-2.	2.2	2
8	Parallelism of intestinal secretory IgA shapes functional microbial fitness. <i>Nature</i> , 2021, 598, 657-661.	27.8	60
9	The Distinct Roles of Sialyltransferases in Cancer Biology and Onco-Immunology. <i>Frontiers in Immunology</i> , 2021, 12, 799861.	4.8	36
10	Granulocyte death mediated by specific antibodies in intravenous immunoglobulin (IVIg). <i>Pharmacological Research</i> , 2020, 154, 104168.	7.1	20
11	The Future of Pharmacology: Towards More Personalized Pharmacotherapy and Reverse Translational Research. <i>Pharmacology</i> , 2020, 105, 1-2.	2.2	13
12	IgA Triggers Cell Death of Neutrophils When Primed by Inflammatory Mediators. <i>Journal of Immunology</i> , 2020, 205, 2640-2648.	0.8	4
13	Human IgA binds a diverse array of commensal bacteria. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	65
14	Unique repertoire of anti-carbohydrate antibodies in individual human serum. <i>Scientific Reports</i> , 2020, 10, 15436.	3.3	18
15	Linking glucocorticoid-induced osteoporosis to osteoimmunology. <i>Cell Death and Disease</i> , 2020, 11, 1026.	6.3	1
16	Inflamm-Aging: Arginase-II as Stage Setter in Age-Related Adipose Tissue Inflammation. <i>Pharmacology</i> , 2020, 105, 489-490.	2.2	1
17	Xenogeneic Neu5Gc and self-glycan Neu5Ac epitopes are potential immune targets in MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	6.0	6
18	Arginase-II promotes melanoma migration and adhesion through enhancing hydrogen peroxide production and STAT3 signaling. <i>Journal of Cellular Physiology</i> , 2020, 235, 9997-10011.	4.1	20

#	ARTICLE	IF	CITATIONS
19	Enhanced Pro-apoptotic Effects of Fe(II)-Modified IVIG on Human Neutrophils. <i>Frontiers in Immunology</i> , 2020, 11, 973.	4.8	4
20	Immune biomarker-based enrichment in sepsis trials. <i>Critical Care</i> , 2020, 24, 58.	5.8	2
21	Secondary-Type Carbohydrate Modification as a Driver of Epithelial-Mesenchymal Transition and Features of Cancer Stem Cells. <i>Pharmacology</i> , 2020, 105, 244-245.	2.2	0
22	Antitumor effects of the GM3(Neu5Gc) ganglioside-specific humanized antibody 14F7hT against Cmah-transfected cancer cells. <i>Scientific Reports</i> , 2019, 9, 9921.	3.3	23
23	Allergy and Atopic Diseases: An Update on Experimental Evidence. <i>International Archives of Allergy and Immunology</i> , 2019, 180, 235-243.	2.1	17
24	The architecture of the IgG anti-carbohydrate repertoire in primary antibody deficiencies. <i>Blood</i> , 2019, 134, 1941-1950.	1.4	19
25	Differential Recognition of Diet-Derived Neu5Gc-Neoantigens on Glycan Microarrays by Carbohydrate-Specific Pooled Human IgG and IgA Antibodies. <i>Bioconjugate Chemistry</i> , 2019, 30, 1565-1574.	3.6	12
26	Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2019, 7, 707-718.	3.4	94
27	Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer. <i>Glycobiology</i> , 2018, 28, 640-647.	2.5	115
28	Recent Advances in Experimental Allergy. <i>International Archives of Allergy and Immunology</i> , 2018, 177, 281-289.	2.1	4
29	Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo. <i>Pharmaceuticals</i> , 2018, 11, 132.	3.8	5
30	A Cartography of Siglecs and Sialyltransferases in Gynecologic Malignancies: Is There a Road Towards a Sweet Future?. <i>Frontiers in Oncology</i> , 2018, 8, 68.	2.8	14
31	Basics of Immunoglobulins as Effector Molecules and Drugs. , 2018, , 133-150.		0
32	Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. <i>Journal of Clinical Investigation</i> , 2018, 128, 4912-4923.	8.2	214
33	Innate lymphoid cells in asthma: cannabinoids on the balance. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 839-841.	5.7	3
34	Antibody repertoire profiling with mimotope arrays. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 314-322.	3.3	18
35	IVIG regulates the survival of human but not mouse neutrophils. <i>Scientific Reports</i> , 2017, 7, 1296.	3.3	38
36	Isolation of Antibodies from Human Plasma, Saliva, Breast Milk, and Gastrointestinal Fluid. <i>Methods in Molecular Biology</i> , 2017, 1643, 23-31.	0.9	5

#	ARTICLE	IF	CITATIONS
37	Clinical Use and Therapeutic Potential of IVIG/SCIG, Plasma-Derived IgA or IgM, and Other Alternative Immunoglobulin Preparations. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2017, 65, 215-231.	2.3	23
38	The Potential Use of Pharmacological Agents to Modulate Orthodontic Tooth Movement (OTM). <i>Frontiers in Physiology</i> , 2017, 8, 67.	2.8	27
39	Synchrotron microbeam irradiation induces neutrophil infiltration, thrombocyte attachment and selective vascular damage in vivo. <i>Scientific Reports</i> , 2016, 6, 33601.	3.3	37
40	Protection from experimental autoimmune encephalomyelitis by polyclonal IgG requires adjuvant-induced inflammation. <i>Journal of Neuroinflammation</i> , 2016, 13, 42.	7.2	8
41	The European Hematology Association Roadmap for European Hematology Research: a consensus document. <i>Haematologica</i> , 2016, 101, 115-208.	3.5	67
42	MicroRNA-155: microtuning the allergic concert. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1035-1036.	5.7	3
43	Basophils exhibit antibacterial activity through extracellular trap formation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1184-1188.	5.7	66
44	Intravenous Immunoglobulin with Enhanced Polyspecificity Improves Survival in Experimental Sepsis and Aseptic Systemic Inflammatory Response Syndromes. <i>Molecular Medicine</i> , 2015, 21, 1002-1010.	4.4	24
45	The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites. <i>Science Translational Medicine</i> , 2015, 7, 269ra1.	12.4	87
46	Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 1231-1248.	5.4	99
47	Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. <i>Journal of Clinical Investigation</i> , 2014, 124, 1810-1820.	8.2	340
48	Protein-glycan interactions as targets of intravenous/subcutaneous immunoglobulin (IVIg/SCIg) preparations. <i>Clinical and Experimental Immunology</i> , 2014, 178, 151-152.	2.6	4
49	IVIg pluripotency and the concept of Fc-sialylation: challenges to the scientist. <i>Nature Reviews Immunology</i> , 2014, 14, 349-349.	22.7	68
50	Microbial glycan microarrays define key features of host-microbial interactions. <i>Nature Chemical Biology</i> , 2014, 10, 470-476.	8.0	191
51	Human IgA Fc Receptor FcγRI (CD89) Triggers Different Forms of Neutrophil Death Depending on the Inflammatory Microenvironment. <i>Journal of Immunology</i> , 2014, 193, 5649-5659.	0.8	32
52	CD Molecules. , 2014, , 1663-1687.		0
53	Alginate-coated chitosan nanogel capacity to modulate the effect of TLR ligands on blood dendritic cells. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2013, 9, 806-817.	3.3	43
54	Cell Death in Immune Thrombocytopenia: Novel Insights and Perspectives. <i>Seminars in Hematology</i> , 2013, 50, S109-S115.	3.4	12

#	ARTICLE	IF	CITATIONS
55	Mechanisms and potential therapeutic targets in allergic inflammation: recent insights. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 1487-1498.	5.7	17
56	Glycomic analysis of human mast cells, eosinophils and basophils. <i>Glycobiology</i> , 2012, 22, 12-22.	2.5	27
57	Update in clinical allergy and immunology. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 1491-1500.	5.7	6
58	Granulocyte Death Regulation by Naturally Occurring Autoantibodies. <i>Advances in Experimental Medicine and Biology</i> , 2012, 750, 157-172.	1.6	7
59	Glucocorticoids on air™. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 144-146.	5.7	4
60	Antibodies recognising sulfated carbohydrates are prevalent in systemic sclerosis and associated with pulmonary vascular disease. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2218-2224.	0.9	36
61	A Differential Concentration-Dependent Effect of IVIg on Neutrophil Functions: Relevance for Anti-Microbial and Anti-Inflammatory Mechanisms. <i>PLoS ONE</i> , 2011, 6, e26469.	2.5	38
62	Dimeric IVIG contains natural anti-Siglec-9 autoantibodies and their anti-idiotypes. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 1030-1037.	5.7	41
63	Targeting Siglecs™ A novel pharmacological strategy for immuno- and glycotherapy. <i>Biochemical Pharmacology</i> , 2011, 82, 323-332.	4.4	81
64	Cell Death Modulation by Intravenous Immunoglobulin. <i>Journal of Clinical Immunology</i> , 2010, 30, 24-30.	3.8	81
65	Expression and Function of Siglec-8 in Human Eosinophils, Basophils, and Mast Cells. , 2009, , 297-313.		3
66	Intravenous immunoglobulin contains a broad repertoire of anticarbohydrate antibodies that is not restricted to the IgG2 subclass. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 1268-1276.e15.	2.9	89
67	DIFFERENT PATTERNS OF SIGLEC-9-MEDIATED NEUTROPHIL DEATH RESPONSES IN SEPTIC SHOCK. <i>Shock</i> , 2009, 32, 386-392.	2.1	23
68	Basic and Clinical Immunology of Siglecs. <i>Annals of the New York Academy of Sciences</i> , 2008, 1143, 61-82.	3.8	144
69	Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: Implications for the clinical use of intravenous immunoglobulins (IVIg). <i>Autoimmunity Reviews</i> , 2008, 7, 453-456.	5.8	58
70	Inhibition of FcÎµRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 499-505.e1.	2.9	144
71	Autophagic-Like Cell Death in Neutrophils Induced by Autoantibodies. <i>Autophagy</i> , 2007, 3, 67-68.	9.1	30
72	Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 1005-1011.	2.9	97

#	ARTICLE	IF	CITATIONS
73	Immunologic and functional evidence for anti- $\alpha$ -Siglec-9 autoantibodies in intravenous immunoglobulin preparations. <i>Blood</i> , 2006, 108, 4255-4259.	1.4	120
74	Sialic acid binding immunoglobulin-like lectins may regulate innate immune responses by modulating the life span of granulocytes. <i>FASEB Journal</i> , 2006, 20, 601-605.	0.5	37
75	Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment. <i>Blood</i> , 2005, 106, 1423-1431.	1.4	212
76	Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, 1185-1190.	2.9	88
77	The Interleukin-13 Production by Peripheral Blood T Cells from Atopic Dermatitis Patients Does Not Require CD2 Costimulation. <i>International Archives of Allergy and Immunology</i> , 2003, 132, 148-155.	2.1	30